News

BenevolentAI appoints Dr John Orloff to its Board of Directors

Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.

London, 9 September, 2021, BenevolentAI has deepened the drug discovery and development expertise on its Board with the appointment of Dr John Orloff as a Non-Executive Director. Dr Orloff joins the BenevolentAI Board as it advances plans to scale its AI platform, partnerships and drug portfolio.

“Technological advances have created a new category of companies that have dramatically changed the way we approach drug discovery research, introducing previously impossible speed, accuracy and scale to the process.” Dr Orloff commented, “BenevolentAI is a rare company in this emerging sector, in that they  have demonstrated in silico, in vitro and clinical validation of their technology, and I believe its unique approach will change how the entire industry discovers and develops drugs.”

As a global R&D and business leader with 25 years of experience in the biopharma industry, Dr Orloff will bring invaluable expertise across research, drug discovery, clinical development, medical affairs, health economics, and regulatory affairs to BenevolentAI’s experienced Board of Directors. He joins Benevolent from Alexion, where he served as Executive Vice President and Global Head of R&D and, over three years, led the expansion of the development pipeline from 3 to 30 programs, spanning over 80 clinical trials from Phase 1 to Phase 4 . Previously, he was Global Head of R&D and Chief Scientific Officer at Baxalta, followed by the roles of Executive Vice President and Head of R&D at Novelion. He also held executive R&D roles at Merck Serono and Novartis.

Dr Francios Nader, Chairman of BenevolentAI, commented; "Dr John Orloff adds invaluable scientific leadership expertise in preclinical research and clinical development to BenevolentAI's Board, and will be a guiding force as the company continues to drive innovation and uncover new treatments with a higher likelihood of clinical success."

Joanna Shields, CEO and Board Director of BenevolentAI, commented, "As the Benevolent platform scales and we accelerate the development of our internal pipeline of novel drugs, Dr. John Orloff brings an impressive track record in R&D and commercialisation to our Board and we warmly welcome John to the team.”

Dr Orloff received his A.B. from Dartmouth College and earned his MD from the University of Vermont College of Medicine, completing his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.


Media inquiries

Rajin Kang

rajin.kang@benevolent.ai 

About BenevolentAI 

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021